CATUG Biotechnology (Suzhou) Co., Ltd. was established in June 2021, with R&D centers and industrialization bases located in Suzhou and Wuhan. As an innovative technology company focusing on nucleic acid process development and application, we aim at providing one-stop CDMO services for the entire industry chain from product development, quality research, clinical application to industrialization of cell therapy and nucleic acid drugs.

With the mission to “build a top process technology platform, lead innovative biotechnology services, and expand the infinite possibilities of life science and technology”, the company grow from several core technical service platforms, covering high-quality industrial plasmid process development and production, mRNA synthesis and delivery full-process process development and production, nucleic acid analytical procedures and quality research. We have cooperation with many pharmaceutical companies and will continue to deploy in the field of new technology applications, devoting to become a model of a new-generation innovative biotechnology industry.

The core teams of CATUG Biotechnology are from well-known domestic and foreign universities including Harvard University, University of California, Ohio University, Northeastern University, Stockholm University, Tsinghua University, Tianjin University, China Pharmaceutical University, Academy of Military Medical Sciences, etc., as well as top international and domestic biopharmaceutical companies, and have rich experiences in industrial technology and management in the field of nucleic acid technology.